US2015224076A1PendingUtilityA1

Compositions comprising 15-ohepa and methods of using the same

54
Assignee: DIGNITY SCIENCES LTDPriority: Jan 30, 2013Filed: Apr 24, 2015Published: Aug 13, 2015
Est. expiryJan 30, 2033(~6.6 yrs left)· nominal 20-yr term from priority
Inventors:Jonathan RoweKevin DuffyJohn Climax
A61P 1/00A61P 1/16A61K 31/557A61K 9/0053A61K 31/202A61K 9/48A61K 31/232
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-OHEPA.

Claims

exact text as granted — not AI-modified
1 . A method for treating or preventing liver disease in a subject comprising, administering to the subject 15-HEPE in an amount effective to treat or prevent liver disease in the subject. 
     
     
         2 . The method of  claim 1  wherein the 15-HEPE is present in a pharmaceutical composition. 
     
     
         3 . The method of  claim 1 , wherein the liver disease is non-alcoholic steatohepatitis. 
     
     
         4 . The method of  claim 2 , wherein the 15-HEPE is present in the pharmaceutical composition in an amount from about 1 mg to about 1000 mg. 
     
     
         5 . The method of  claim 2 , wherein the 15-HEPE represents at least about 1% to about 95% of all fatty acids present in the pharmaceutical composition. 
     
     
         6 . The method of  claim 2 , wherein the 15-HEPE represents at least about 60%, by weight, of all fatty acids present in the pharmaceutical composition. 
     
     
         7 . The method of  claim 2 , wherein the 15-HEPE represents at least about 70%, by weight, of all fatty acids present in the pharmaceutical composition. 
     
     
         8 . The method of  claim 2 , wherein the 15-HEPE represents at least about 90%, by weight, of all fatty acids present in the pharmaceutical composition. 
     
     
         9 . The method of  claim 2 , wherein the 15-HEPE represents substantially all fatty acids present in the pharmaceutical composition. 
     
     
         10 . The method of  claim 2 , wherein the 15-HEPE represents all fatty acids present in the pharmaceutical composition. 
     
     
         11 . The method of  claim 2  wherein the composition is free of any other omega-3 fatty acids. 
     
     
         12 . The method of  claim 2 , wherein the administering step includes administering the pharmaceutical composition to the subject about 1 to about 4 times per day. 
     
     
         13 . The method of  claim 2 , wherein the pharmaceutical composition is present in one or more dosage units. 
     
     
         14 . The method of  claim 13 , wherein the one or more dosage units comprise orally deliverable capsules. 
     
     
         15 . The method of  claim 1 , wherein the subject has a predisposition to and/or a diagnosis of the liver disease. 
     
     
         16 . The method of  claim 1 , wherein the liver disease is non-alcoholic fatty liver disease (NAFLD). 
     
     
         17 . The method of  claim 2 , wherein the pharmaceutical composition comprises about 0.1% to about 99%, by weight, 15-HEPE. 
     
     
         18 . The method of  claim 2 , wherein the pharmaceutical composition comprises at least about 50%, by weight, 15-HEPE.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.